Terms: = Germ cell tumor AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1
834 results:
1. AB042. Combined anti-PD-L1 and anti-vegfr2 therapy promotes the antitumor immune response in glioblastoma multiforme by reprogramming tumor microenvironment.
Lin Y; Wang H; Zhou Y
Chin Clin Oncol; 2024 Aug; 13(Suppl 1):AB042. PubMed ID: 39295360
[TBL] [Abstract] [Full Text] [Related]
2. Angiogenic biomarkers of response to treatment with peptide receptor radionuclide therapy in neuroendocrine tumours.
Strzelczyk J; Wójcik-Giertuga M; Makulik K; Rosiek V; Kamiński G; Kajdaniuk D; Kos-Kudła B
Endokrynol Pol; 2024; 75(4):412-418. PubMed ID: 39279310
[TBL] [Abstract] [Full Text] [Related]
3. Semaxanib, a VEGF inhibitor, suppresses melanogenesis by modulating CRTC3 independently of VEGF signaling.
Kwon H; Lee JH; Yoo JM; Nguyen H; An H; Chang SE; Song Y
J Dermatol Sci; 2024 Sep; 115(3):121-129. PubMed ID: 39127591
[TBL] [Abstract] [Full Text] [Related]
4. Juglone suppresses vasculogenic mimicry in glioma through inhibition of HuR-mediated VEGF-A expression.
Luo C; Chen G; Li R; Peng S; Zhang P; Wang F; Yu S; Zhu Y; Zhang J
Biochem Pharmacol; 2024 Sep; 227():116458. PubMed ID: 39102993
[TBL] [Abstract] [Full Text] [Related]
5. Exploring the multifaceted antitumor activity of axitinib in lung carcinoids.
Oldani M; Cantone MC; Gaudenzi G; Carra S; Dicitore A; Saronni D; Borghi MO; Lombardi A; Caraglia M; Persani L; Vitale G
Front Endocrinol (Lausanne); 2024; 15():1433707. PubMed ID: 39050569
[TBL] [Abstract] [Full Text] [Related]
6. Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry.
Yang Q; Li Q; Fan H
Arch Dermatol Res; 2024 Jul; 316(7):447. PubMed ID: 38958761
[TBL] [Abstract] [Full Text] [Related]
7. HNRNPA2B1 stabilizes NFATC3 levels to potentiate its combined actions with FOSL1 to mediate vasculogenic mimicry in GBM cells.
Wang H; Shi Y; Zhou X; Zhang L; Yang A; Zhou D; Ma T
Cell Biol Toxicol; 2024 Jun; 40(1):44. PubMed ID: 38862832
[TBL] [Abstract] [Full Text] [Related]
8. Vasorin promotes endothelial differentiation of glioma stem cells via stimulating the transcription of vegfr2.
Qin Z; Zhong Y; Li P; Ma Z; Kang H; Huang Y; Zhong Y; Wang L
FASEB J; 2024 May; 38(10):e23682. PubMed ID: 38780524
[TBL] [Abstract] [Full Text] [Related]
9. Phase I/II Study of a Vascular Endothelial Growth Factor Receptor Vaccine in Patients With NF2-Related Schwannomatosis.
Tamura R; Yamanobe Y; Fujioka M; Morimoto Y; Fukumura M; Nakaya M; Oishi Y; Sato M; Ueda R; Fujiwara H; Hikichi T; Noji S; Oishi N; Ozawa H; Ogawa K; Kawakami Y; Ohira T; Yoshida K; Toda M
J Clin Oncol; 2024 Jul; 42(21):2578-2587. PubMed ID: 38776485
[TBL] [Abstract] [Full Text] [Related]
10. mRNA markers for survival prediction in glioblastoma multiforme patients: a systematic review with bioinformatic analyses.
Azimi P; Yazdanian T; Ahmadiani A
BMC Cancer; 2024 May; 24(1):612. PubMed ID: 38773447
[TBL] [Abstract] [Full Text] [Related]
11. vegfr2 blockade inhibits glioblastoma cell proliferation by enhancing mitochondrial biogenesis.
Guo M; Zhang J; Han J; Hu Y; Ni H; Yuan J; Sun Y; Liu M; Gao L; Liao W; Ma C; Liu Y; Li S; Li N
J Transl Med; 2024 May; 22(1):419. PubMed ID: 38702818
[TBL] [Abstract] [Full Text] [Related]
12. Unlocking Hope: Anti-vegfr inhibitors and their potential in glioblastoma treatment.
Berro A; Assi A; Farhat M; Hatoum L; Saad JP; Mohanna R; Bechara AMA; Prince G; Hachem MCR; Zalaquett Z; Kourie HR
Crit Rev Oncol Hematol; 2024 Jun; 198():104365. PubMed ID: 38677355
[TBL] [Abstract] [Full Text] [Related]
13. Mutational landscape of oral mucosal melanoma based on comprehensive cancer genomic profiling tests in a Japanese cohort.
Ichimura N; Urata Y; Kobayashi T; Hibi H
Oral Oncol; 2024 May; 152():106807. PubMed ID: 38615585
[TBL] [Abstract] [Full Text] [Related]
14. Recent advances in tyrosine kinase inhibitors vegfr 1-3 for the treatment of advanced metastatic melanoma.
Sobczuk P; Cholewiński M; Rutkowski P
Expert Opin Pharmacother; 2024 Apr; 25(5):501-510. PubMed ID: 38607407
[TBL] [Abstract] [Full Text] [Related]
15. Single-cell sequencing reveals vegfr as a potential target for CAR-T cell therapy in chordoma.
Wu H; Li X; Zhang B; Liu P; Qi M; Du Y; Zhang C; Duan W; Chen Z
Br J Cancer; 2024 Jun; 130(10):1609-1620. PubMed ID: 38605247
[TBL] [Abstract] [Full Text] [Related]
16. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
[TBL] [Abstract] [Full Text] [Related]
17. Grafted Sertoli cells Exert Immunomodulatory Non-Immunosuppressive Effects in Preclinical Models of Infection and Cancer.
Chiappalupi S; Salvadori L; Borghi M; Mancuso F; Pariano M; Riuzzi F; Luca G; Romani L; Arato I; Sorci G
Cells; 2024 Mar; 13(6):. PubMed ID: 38534388
[TBL] [Abstract] [Full Text] [Related]
18. VEGF/vegfr axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives.
Malekan M; Haass NK; Rokni GR; Gholizadeh N; Ebrahimzadeh MA; Kazeminejad A
Life Sci; 2024 May; 345():122563. PubMed ID: 38508233
[TBL] [Abstract] [Full Text] [Related]
19. Vasorin Exocytosed from Glioma cells Facilitates Angiogenesis via vegfr2/AKT Signaling Pathway.
Zhong Y; Kang H; Ma Z; Li J; Qin Z; Zhang Z; Li P; Zhong Y; Wang L
Mol Cancer Res; 2024 Jul; 22(7):668-681. PubMed ID: 38488456
[TBL] [Abstract] [Full Text] [Related]
20. [Systemic treatment of adult gliomas: a narrative review].
Mangel L
Magy Onkol; 2024 Mar; 68(1):67-75. PubMed ID: 38484377
[TBL] [Abstract] [Full Text] [Related]
[Next]
